Johnson & Johnson (NYSE:JNJ) Position Raised by Ipswich Investment Management Co. Inc.


Share on StockTwits

Ipswich Investment Management Co. Inc. increased its holdings in Johnson & Johnson (NYSE:JNJ) by 2.2% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 52,113 shares of the company’s stock after buying an additional 1,101 shares during the period. Johnson & Johnson accounts for approximately 2.4% of Ipswich Investment Management Co. Inc.’s portfolio, making the stock its 5th largest holding. Ipswich Investment Management Co. Inc.’s holdings in Johnson & Johnson were worth $8,565,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of JNJ. Norges Bank purchased a new stake in Johnson & Johnson during the fourth quarter valued at about $4,370,566,000. Sanders Capital LLC purchased a new stake in Johnson & Johnson during the fourth quarter valued at about $1,126,076,000. Morgan Stanley raised its position in Johnson & Johnson by 7.3% during the fourth quarter. Morgan Stanley now owns 24,111,028 shares of the company’s stock valued at $3,794,594,000 after purchasing an additional 1,638,263 shares in the last quarter. Bank of New York Mellon Corp raised its position in Johnson & Johnson by 5.4% during the fourth quarter. Bank of New York Mellon Corp now owns 31,958,260 shares of the company’s stock valued at $5,029,590,000 after purchasing an additional 1,628,229 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund raised its position in Johnson & Johnson by 574.1% during the fourth quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,557,719 shares of the company’s stock valued at $245,154,000 after purchasing an additional 1,326,651 shares in the last quarter. Institutional investors own 67.25% of the company’s stock.

NYSE JNJ opened at $161.25 on Monday. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.48 and a quick ratio of 1.24. The stock has a market capitalization of $424.52 billion, a PE ratio of 25.35, a PEG ratio of 3.06 and a beta of 0.70. Johnson & Johnson has a 1 year low of $133.65 and a 1 year high of $173.65. The business’s 50-day moving average is $160.97 and its 200 day moving average is $154.54.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Monday, January 25th. The company reported $1.86 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.82 by $0.04. The company had revenue of $22.50 million for the quarter, compared to analysts’ expectations of $21.62 billion. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. Johnson & Johnson’s quarterly revenue was up 8.7% on a year-over-year basis. During the same period last year, the firm earned $1.88 earnings per share. As a group, equities research analysts anticipate that Johnson & Johnson will post 7.99 earnings per share for the current year.

A number of research firms have weighed in on JNJ. JPMorgan Chase & Co. raised their price target on Johnson & Johnson from $157.00 to $175.00 and gave the company a “neutral” rating in a research report on Wednesday, January 27th. Cowen lifted their price objective on Johnson & Johnson from $170.00 to $195.00 and gave the stock an “outperform” rating in a report on Wednesday, January 27th. Cantor Fitzgerald lifted their price objective on Johnson & Johnson from $180.00 to $200.00 and gave the stock an “overweight” rating in a report on Tuesday, January 26th. Morgan Stanley lifted their price objective on Johnson & Johnson from $178.00 to $187.00 and gave the stock an “overweight” rating in a report on Wednesday, January 27th. Finally, Credit Suisse Group lifted their price objective on Johnson & Johnson from $168.00 to $193.00 and gave the stock an “outperform” rating in a report on Wednesday, January 27th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have given a buy rating to the company. Johnson & Johnson has a consensus rating of “Buy” and a consensus target price of $178.60.

About Johnson & Johnson

Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Recommended Story: Non-Fungible Token (NFT)

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.